Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer

NCT05250336 is registered in ClinicalTrials.gov with Sanjay Gandhi Postgraduate Institute of Medical Sciences as lead sponsor.

NCT NCT05250336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05250336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer
Lead sponsor
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Phase
Observational
Overall status
Unknown status
Start date
January 19, 2019
Completion date
September 30, 2022
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, programmed cell death ligand 1, tumor infiltrating lymphocytes